[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100540245":3},{"organization":4,"armGroups":7,"interventions":25,"overallOfficials":45,"centralContacts":50,"locations":59,"responsibleParty":164,"collaborators":31,"id":167,"slug":168,"hasResults":169,"nctId":170,"briefTitle":171,"officialTitle":172,"acronym":31,"eligibilityCriteria":173,"healthyVolunteers":169,"sex":174,"minAge":175,"maxAge":176,"enrollmentInfo":177,"targetDuration":31,"studyType":180,"phases":181,"briefSummary":183,"conditions":184,"keywords":186,"overallStatus":62,"whyStopped":31,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":192,"startDateStruct":195,"completionDateStruct":197,"leadSponsor":199,"locationsCount":200},{"fullName":5,"class":6},"Fudan University","OTHER",[8,15,20],{"label":9,"type":10,"description":11,"interventionNames":12},"Group A (synchronous treatment group)","EXPERIMENTAL","Patients received 4 cycles of Sintilimab combined with pegaspargase therapy, with each cycle lasting 3 weeks, for a total of 4 cycles. Concurrently, they received radiotherapy treatment (IMRT, 50-56Gy, starting within 21 days after the first Sintilimab treatment).",[13,14],"Drug: Sintilimab+Pegaspargase","Radiation: IMRT",{"label":16,"type":10,"description":17,"interventionNames":18},"Group B (sequential treatment group)","Patients received 4 cycles of the PGEMOX regimen chemotherapy. Each cycle lasted 3 weeks, with sequential radiotherapy (IMRT, 50-56Gy) administered within 4 weeks after the last chemotherapy cycle.",[19,14],"Drug: P-GemOx",{"label":21,"type":10,"description":22,"interventionNames":23},"Group C (sandwiched radiotherapy group)","Patients received 2 cycles of the GELAD regimen chemotherapy initially, with each cycle lasting 3 weeks. After the second cycle of chemotherapy, radiotherapy (IMRT, 50-56Gy) was administered within 4 weeks. Following the completion of radiotherapy, they received an additional 2 cycles of the GELAD regimen chemotherapy.",[24,14],"Drug: GELAD",[26,32,36,40],{"type":27,"name":28,"description":29,"armGroupLabels":30,"otherNames":31},"DRUG","Sintilimab+Pegaspargase","1. Sintilimab, 200mg intravenous drip, on day 1;\n2. pegaspargase, 2000U\u002Fm\\^2, capped at 3750U, intramuscular, day 1;",[9],null,{"type":27,"name":33,"description":34,"armGroupLabels":35,"otherNames":31},"P-GemOx","1. pegaspargase 2000U\u002Fm\\^2, capped at 3750U on day 1, intramuscular;\n2. gemcitabine 1.0g\u002Fm\\^2 on day 1 and day 8, intravenous drip;\n3. oxaliplatin 130mg\u002Fm\\^2 on day 1, intravenous drip",[16],{"type":27,"name":37,"description":38,"armGroupLabels":39,"otherNames":31},"GELAD","1. gemcitabine 1.0g\u002Fm\\^2 on day 1, intravenous drip;\n2. etoposide 60mg\u002Fm\\^2 on day 1-3, intravenous drip;\n3. pegaspargase 2000U\u002Fm\\^2, capped at 3750U on day 1,intramuscular;\n4. dexamethasone 20mg on day 1-4, intravenous drip.",[21],{"type":41,"name":42,"description":43,"armGroupLabels":44,"otherNames":31},"RADIATION","IMRT","Intensity modulated radiotherapy (50-56Gy)",[9,16,21],[46],{"name":47,"affiliation":48,"role":49},"Rong Tao, MD","Fudan Cancer Hospital","STUDY_CHAIR",[51,55],{"name":47,"role":52,"phone":53,"phoneExt":31,"email":54},"CONTACT","8621-64175590","rtao@shca.org.cn",{"name":56,"role":52,"phone":57,"phoneExt":31,"email":58},"Chuanxu Liu, MD","021-64175590","liuchuanxu@shca.org.cn",[60,81,97,113,123,135,150],{"facility":61,"status":62,"city":63,"state":64,"zip":65,"country":66,"countryCode":67,"cosmosGeoPoint":68,"geoPoint":73,"contacts":74},"Cancer Hospital of Fujian Province","RECRUITING","Fuzhou","Fujian","350003","China","CN",{"type":69,"coordinates":70},"Point",[71,72],119.30611,26.06139,{"lat":72,"lon":71},[75,79],{"name":76,"role":52,"phone":77,"phoneExt":31,"email":78},"Jiesong Wang, MD","0086591-83660063","349697291@qq.com",{"name":76,"role":80,"phone":31,"phoneExt":31,"email":31},"PRINCIPAL_INVESTIGATOR",{"facility":82,"status":62,"city":83,"state":84,"zip":85,"country":66,"countryCode":67,"cosmosGeoPoint":86,"geoPoint":90,"contacts":91},"Nantong Cancer Hospital","Nantong","Jiangsu","226006",{"type":69,"coordinates":87},[88,89],120.87472,32.03028,{"lat":89,"lon":88},[92,96],{"name":93,"role":52,"phone":94,"phoneExt":31,"email":95},"Xiaohong Xu, MD","0086513-86712049","xhx107@163.com",{"name":93,"role":80,"phone":31,"phoneExt":31,"email":31},{"facility":98,"status":62,"city":99,"state":100,"zip":101,"country":66,"countryCode":67,"cosmosGeoPoint":102,"geoPoint":106,"contacts":107},"Shanghai Eye Ear Nose and Throat Hospital，Fudan University","Shanghai","Shanghai Municipality","200000",{"type":69,"coordinates":103},[104,105],121.45806,31.22222,{"lat":105,"lon":104},[108,112],{"name":109,"role":52,"phone":110,"phoneExt":31,"email":111},"Hao Ding, MD","008621-64377134","eentding@163.com",{"name":109,"role":80,"phone":31,"phoneExt":31,"email":31},{"facility":114,"status":62,"city":99,"state":100,"zip":115,"country":66,"countryCode":67,"cosmosGeoPoint":116,"geoPoint":118,"contacts":119},"Fudan University Shanghai Cancer Center","200032",{"type":69,"coordinates":117},[104,105],{"lat":105,"lon":104},[120,121,122],{"name":47,"role":52,"phone":53,"phoneExt":31,"email":54},{"name":56,"role":52,"phone":53,"phoneExt":31,"email":58},{"name":47,"role":80,"phone":31,"phoneExt":31,"email":31},{"facility":124,"status":62,"city":99,"state":100,"zip":125,"country":66,"countryCode":67,"cosmosGeoPoint":126,"geoPoint":128,"contacts":129},"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","200092",{"type":69,"coordinates":127},[104,105],{"lat":105,"lon":104},[130,134],{"name":131,"role":52,"phone":132,"phoneExt":31,"email":133},"Jiangbo Wan, MD","008621-25077607","wangjiangbo@xinhuamed.com.cn",{"name":131,"role":80,"phone":31,"phoneExt":31,"email":31},{"facility":136,"status":62,"city":137,"state":138,"zip":139,"country":66,"countryCode":67,"cosmosGeoPoint":140,"geoPoint":144,"contacts":145},"Zhejiang Cancer Hospital","Hangzhou","Zhejiang","310022",{"type":69,"coordinates":141},[142,143],120.16142,30.29365,{"lat":143,"lon":142},[146],{"name":147,"role":52,"phone":148,"phoneExt":31,"email":149},"Cong Li, MD","0086571-8812-2222","licong@zjcc.org.cn",{"facility":151,"status":62,"city":152,"state":138,"zip":31,"country":66,"countryCode":67,"cosmosGeoPoint":153,"geoPoint":157,"contacts":158},"People's Hospital of Ningbo University","Ningbo",{"type":69,"coordinates":154},[155,156],121.54945,29.87819,{"lat":156,"lon":155},[159,163],{"name":160,"role":52,"phone":161,"phoneExt":31,"email":162},"Dong Chen, MD","0086574-87016888","shanying0626@163.com",{"name":160,"role":80,"phone":31,"phoneExt":31,"email":31},{"type":80,"investigatorFullName":165,"investigatorTitle":166,"investigatorAffiliation":5,"oldNameTitle":31,"oldOrganization":31},"Rong Tao","Prof.","100540245","phase-2-screening-study-of-combined-sequential-chemotherapy-and-radiation-therapy-for-early-stage-nkt-cell-lymphoma-100540245",false,"NCT06314334","Screening Study of Combined Sequential Chemotherapy and Radiation Therapy for Early-stage NK\u002FT-cell Lymphoma","A Multicenter, Randomized, Controlled Phase II Screening Study of Combined Sequential Chemotherapy and Radiation Therapies for Early-stage Natural Killer\u002FT-cell Lymphoma (IE\u002FIIE)","Inclusion Criteria:\n\n* Patients who meet the diagnostic criteria for NKTCL (WHO-2016) based on pathological examination.\n* Primary lesions located in the upper respiratory and digestive tract such as the nasal cavity, sinuses, nasopharynx, oropharynx, or oral cavity, with clinical staging of IE\u002FIIE based on PET\u002FCT and bone marrow examination according to the Lugano 2014 criteria.\n* Evaluated for lymphoma response according to the Lugano 2014 criteria, with at least one measurable lesion or lesion assessable by PET\u002FCT.\n* No prior treatment with chemotherapy, radiotherapy, immunotherapy, or biological therapy for lymphoma.\n* Age between 18 and 75 years, both genders.\n* Eastern Cooperative Oncology Group performance status (ECOG) score of 0-2.\n* Must have adequate organ and bone marrow function, defined as follows:\n\nHematology: Absolute neutrophil count (ANC) ≥1.0×10\\^9\u002FL, platelet count (PLT) ≥75×10\\^9\u002FL, hemoglobin (Hb) ≥90g\u002FL; no administration of granulocyte colony-stimulating factor, platelet transfusion, or red blood cell transfusion in the previous 14 days.\n\nLiver function: Total bilirubin (TBIL) ≤1.5 times the upper limit of normal (ULN); alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2×ULN.\n\nRenal function: Serum creatinine (Cr) ≤1.5×ULN. Coagulation function: Plasma fibrinogen ≥1.5g\u002FL. Cardiac function: Left ventricular ejection fraction (LVEF) ≥50%, no acute myocardial infarction, arrhythmia, or atrioventricular conduction block of grade I or above on electrocardiogram.\n\n* Willing to comply with the study protocol, follow-up plan, and laboratory and ancillary investigations.\n\nExclusion Criteria:\n\n* Patients co-infected with HCV, HIV, or HBV with plasma HBV-DNA \\>10\\^3\u002Fml.\n* Patients with a history of pancreatitis.\n* Patients with acute or systemic infections requiring intravenous antibiotic therapy.\n* Patients with severe complications such as hemophagocytic syndrome, DIC, etc.\n* Significant organ dysfunction: such as respiratory failure, chronic congestive heart failure with NYHA class ≥2, decompensated liver or renal dysfunction, uncontrolled hypertension and diabetes despite aggressive treatment, and cardiovascular thrombotic or hemorrhagic events in the past 6 months.\n* Patients with a history of autoimmune diseases who are not suitable for treatment with immune checkpoint inhibitors.\n* Pregnant and lactating women.\n* Patients with psychiatric disorders.\n* Known allergies to drugs in the chemotherapy regimen.\n* Patients with concomitant other tumors requiring surgery or chemotherapy within the past 6 months.\n* Currently using other experimental drugs.","ALL","18 Years","75 Years",{"count":178,"type":179},210,"ESTIMATED","INTERVENTIONAL",[182],"PHASE2","Extranodal NK\u002FT-cell lymphoma, nasal type (NKTCL) is a common malignant tumor in East Asian populations, often starting in the nasal cavity and spreading to other organs. Associated with EBV infection, NKTCL is aggressive. Early-stage patients typically receive chemo and radiotherapy, with promising outcomes. Recent studies show the potential of immune checkpoint inhibitors in NKTCL treatment. However, optimal treatment sequencing and efficacy remain unclear. This study aims to compare three strategies: (A) Pegaspargase with Sintilimab and radiotherapy; (B) chemo then radiotherapy (PGemOx); (C) sandwich chemoradiotherapy (GELAD). The goal is to identify the best treatment based on 24-month progression-free survival.",[185],"Natural Killer\u002FT-Cell Lymphoma, Nasal and Nasal-Type",[187,188,189,190],"Chemotherapy","Radiation therapy","Immune checkpoint inhibitor","Pegaspargase","2026-04-03",{"date":193,"type":194},"2026-04-09","ACTUAL",{"date":196,"type":194},"2024-03-04",{"date":198,"type":179},"2028-12-30",{"name":5,"class":6},7]